Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 16 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 7 | 4 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 3 | 1 | 2 | 1 | 0 |
| 2M Ago | 1 | 3 | 0 | 0 | 0 |
| 3M Ago | 0 | 3 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $1046.81, a high estimate of $1189.00, and a low estimate of $720.00. This current average has increased by 1.92% from the previous average price target of $1027.10.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on...
Login or create a forever free account to read this news
Sign up/Log in